However, the function of these pathways in tumor maintenance of the pancreatic lineage still needs further elucidation, since a better understanding of the contribution of K-RAS effectors to tumor maintenance might help to identify therapies alternative to targeting K-RAS itself. The gene discussed is KRAS; the disease is neoplasm.